Nrx Pharmaceuticals, Inc. (NRXP)

Trade NRXP now with
4/21/2022 8:50:02 AM NRx Files Breakthrough Therapy Designation Request For ZYESAMI In Subgroup Of Patients With Critical COVID-19
3/31/2022 8:25:47 AM NRx:I-SPY COVID Trial Shows No Benefit With Addition Of ZYESAMI When Given By Mouth Inhalation In Ill COVID-19 Patients
3/31/2022 8:21:49 AM NRx Pharma FY Net Loss $93.1 Mln Or $1.98/shr Vs. Loss Of $51.8 Mln Or $1.51/shr Prior Year
3/18/2022 5:52:22 AM NRx Names Ira Strassberg As CFO
3/18/2022 5:12:38 AM NRx Pharma Appoints Ira Strassberg As CFO And Treasurer
3/8/2022 10:32:59 PM NRx Pharma Names Robert Besthof Interim CEO
2/15/2022 8:36:11 AM NRx Pharma : US National Institutes Of Health Study Of ZYESAMI In Critical COVID-19 Cleared To Complete Full Enrollment
2/2/2022 8:00:22 PM NRx Pharmaceuticals Announces Closing Of $25 Mln Private Placement
1/31/2022 8:00:05 AM NRx Pharma Announces $25 Mln Private Placement Priced At Premium To Market
1/27/2022 6:54:41 AM NRx : Scientific Evidence Shows BriLife Vaccine May Produce Effective Levels Of Neutralizing Antibody Against Omicron
1/26/2022 6:54:26 AM NRx Receives Initial Report Of Patient Safety And Survival From Right To Try Use Of ZYESAMI
1/5/2022 6:52:29 AM NRx Submits EUA Application To FDA For ZYESAMI To Treat Patients At Immediate Risk Of Death From COVID-19
1/3/2022 7:18:45 AM NRx Pharma Files Provisional Patent For Stable Compositions Of Aviptadil Suitable For Human Use